Frunexian
Frunexian is currently the only intravenous small-molecule Factor XIa antagonist in active development for acute indications.
In vivo studies with frunexian have consistently demonstrated that it can be a potent inhibitor of thrombosis, while minimizing the risk of unwanted bleeding.
Two Phase 1 studies with frunexian in humans have shown a marked dose-proportional increase in the aPTT for both single dose and continuous multiple doses. There was no appreciable change in PT with plasma concentration or dose in either part of the study, validating its specific actions on contact-activated coagulation.
Frunexian was generally well tolerated in both studies.
There was also consistent dose-dependent inhibition of Factor XIa by frunexian.
